2020/11/10 by Manuela Fernández Pinto · 1 voice
Decision Sciences · Pharmacology, Toxicology and Pharmaceutics · #Academic Publishing and Open Access #Pharmaceutical industry and healthcare #scientometrics and bibliometrics research
paper · pdf · doi:10.3389/frma.2020.588331
openalex publication_date 2020/11/10 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
Financial conflicts of interest, several cases of scientific fraud, and research limitations from strong intellectual property laws have all led to questioning the epistemic and social justice appropriateness of industry-funded research. At first sight, the ideal of Open Science, which promotes transparency, sharing, collaboration, and accountability, seems to target precisely the type of limitations uncovered in commercially-driven research. The Open Science movement, however, has primarily focused on publicly funded research, has actively encouraged liaisons with the private sector, and has also created new strategies for commercializing science. As a consequence, I argue that Open Science ends up contributing to the commercialization of science, instead of overcoming its limitations. I use the examples of research publications and citizen science to illustrate this point. Accordingly, the asymmetry between private and public science, present in the current plea to open science, ends up compromising the values of transparency, democracy, and accountability.